The Netherlands Cancer Institute (NKI) in Amsterdam is a Comprehensive Cancer Centre combining a hospital and research laboratories in a single independent organization.
The research group of Reuven Agami at the division of Oncogenomics is interested in the identification of novel cellular vulnerabilities that can be exploited for cancer therapies. For this purpose, we develop innovative genomic and functional genetic tools, and use biochemical and bioinformatics tools to understand the underling mechanisms.